ATE228564T1 - Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden - Google Patents

Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden

Info

Publication number
ATE228564T1
ATE228564T1 AT92919917T AT92919917T ATE228564T1 AT E228564 T1 ATE228564 T1 AT E228564T1 AT 92919917 T AT92919917 T AT 92919917T AT 92919917 T AT92919917 T AT 92919917T AT E228564 T1 ATE228564 T1 AT E228564T1
Authority
AT
Austria
Prior art keywords
hepatitis
composition
virus polypeptides
multiple immunoreactive
immunoreactive
Prior art date
Application number
AT92919917T
Other languages
English (en)
Inventor
Amy J Weiner
Michael Houghton
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25056174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE228564(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE228564T1 publication Critical patent/ATE228564T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT92919917T 1991-09-13 1992-09-11 Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden ATE228564T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75957591A 1991-09-13 1991-09-13
PCT/US1992/007683 WO1993006126A1 (en) 1991-09-13 1992-09-11 Immunoreactive hepatitis c virus polypeptide compositions

Publications (1)

Publication Number Publication Date
ATE228564T1 true ATE228564T1 (de) 2002-12-15

Family

ID=25056174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92919917T ATE228564T1 (de) 1991-09-13 1992-09-11 Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden

Country Status (16)

Country Link
US (6) US5756312A (de)
EP (1) EP0608261B1 (de)
JP (5) JPH06511149A (de)
AT (1) ATE228564T1 (de)
AU (1) AU679429B2 (de)
BG (1) BG62973B1 (de)
CA (1) CA2116764C (de)
DE (1) DE69232859T2 (de)
DK (1) DK0608261T3 (de)
ES (1) ES2182822T3 (de)
FI (1) FI112438B (de)
HU (1) HU227510B1 (de)
PL (2) PL171972B1 (de)
RO (1) RO116199B1 (de)
RU (2) RU2136311C1 (de)
WO (1) WO1993006126A1 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
HU227510B1 (en) * 1991-09-13 2011-07-28 Novartis Vaccines & Diagnostic Immunoreactive hepatitis c virus polypeptide compositions
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
CA2142007C (en) * 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
US7157226B1 (en) 1993-04-27 2007-01-02 Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
US7255997B1 (en) 1993-04-27 2007-08-14 N.V. Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
JPH08510240A (ja) 1993-05-12 1996-10-29 カイロン コーポレイション Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US6555114B1 (en) 1993-11-04 2003-04-29 Innogenetics N.V. Immunodominant human T-cell epitopes of hepatitis C virus
CN1148578C (zh) 1994-07-25 2004-05-05 罗切诊断学有限公司 免疫测定特异抗体的方法、所用试剂、抗原及其用途
DE69526636D1 (de) * 1994-07-29 2002-06-13 Innogenetics Nv Gereinigte hepatitis-c-virus hüllproteine zur diagnostischen und therapeutischen verwendung
AU702436B2 (en) 1994-10-21 1999-02-18 Innogenetics N.V. New sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
US7235394B1 (en) 1995-08-29 2007-06-26 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US7045363B2 (en) * 1996-05-01 2006-05-16 Fujirebio Inc. Nucleic acid-bound polypeptide method of producing nucleic acid-bound polypeptide and immunoassay using the polypeptide
US6001613A (en) * 1996-05-24 1999-12-14 Board Of Regents Of University Of Nebraska Plasmid bearing a cDNA copy of the genome of bovine viral diarrhea virus, chimeric derivatives thereof, and method of producing an infectious bovine viral diarrhea virus using said plasmid
DE69739268D1 (de) 1996-11-08 2009-04-02 Us Gov Health & Human Serv Herstellung und reinigung von hepatitis c virus-ähnlichen partikeln
EP0870830A3 (de) * 1997-02-10 2004-02-25 Advanced Life Science Institute, Inc. Chimäres Hepatitis C-Virusantigen
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
WO1999024466A2 (en) * 1997-11-06 1999-05-20 Innogenetics N.V. Multi-mer peptides derived from hepatitis c virus envelope proteins for diagnostic use and vaccination purposes
US6451306B1 (en) 1998-04-15 2002-09-17 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US6815431B2 (en) 1998-04-15 2004-11-09 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US7157435B2 (en) 1998-04-15 2007-01-02 The Regents Of The University Of California Methods for modulation of the effects of aging on the primate brain
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US7052830B1 (en) * 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
US7108855B2 (en) * 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US6548634B1 (en) * 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US20030180284A1 (en) * 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
US7091324B2 (en) 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
CA2358915C (en) 1998-12-31 2010-06-01 Chiron Corporation Modified hiv env polypeptides
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US6740323B1 (en) 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
EP1535628B1 (de) * 1999-11-24 2013-07-31 Novartis Vaccines and Diagnostics, Inc. Hbv/hcv virus-ähnliche teilchen
CA2416408A1 (en) * 2000-07-19 2002-01-31 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
DE60130998T2 (de) 2000-08-17 2008-07-17 Tripep Ab Ribavirin-enthaltende vakzine
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
WO2002022155A1 (en) 2000-09-13 2002-03-21 Hawaii Biotechnology Group, Inc. Immunogenic composition of hepatitis c and methods of use thereof
RU2195668C2 (ru) * 2001-02-12 2002-12-27 Мешандин Алексей Гаврилович Способ постановки реакции агглютинационного иммунологического анализа
AU2002322358B2 (en) * 2001-06-29 2009-06-18 Novartis Vaccines And Diagnostics, Inc. HCV E1E2 vaccine compositions
EP2412242A3 (de) * 2001-07-05 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Polypeptide vom HIV-Typ C codierende Polynucleotide, Polypeptide und deren Verwendung
WO2003004657A1 (en) * 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
EP1427806A4 (de) * 2001-08-31 2006-04-26 Chiron Corp Antigene hiv-typ-b-polypeptide codierende polynukleotide, polypeptide und verwendungen davon
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
RU2357974C2 (ru) * 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
CA2525825A1 (en) 2003-05-15 2005-01-27 Chiron Corporation Hiv polynucleotides and polypeptides derived from botswana mj4
US20050202036A1 (en) * 2003-07-22 2005-09-15 Branch Andrea D. Alternate reading frame polypeptides drived from hepatitis C and methods of their use
WO2005017125A2 (en) * 2003-08-14 2005-02-24 California Institute Of Molecular Medicine Method for isolation and replication of infectious human hepatitis-c virus
ES2596753T3 (es) 2003-08-29 2017-01-11 Fujirebio Europe N.V. Nuevo clado del virus de la hepatitis C y secuencias prototipo del mismo
CA2585672A1 (en) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
CA2618429A1 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
US8071561B2 (en) * 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
WO2009034190A2 (en) * 2007-09-14 2009-03-19 Genimmune N.V. Affinity tag
US8153590B2 (en) 2007-09-28 2012-04-10 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
FI3604510T3 (fi) 2009-03-30 2025-06-26 Alexion Pharma Inc Vastalääkkeitä tekijä xa:n estäjille ja menetelmiä niiden käyttämiseksi
US20100322943A1 (en) 2009-06-17 2010-12-23 Thomas Cantor Therapeutic and diagnostic affinity purified specific polyclonal antibodies
ES2605801T3 (es) 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
ES2702318T3 (es) 2011-07-06 2019-02-28 Glaxosmithkline Biologicals Sa Emulsiones catiónicas de aceite en agua
CN103781470A (zh) 2011-07-06 2014-05-07 诺华股份有限公司 包含核酸的水包油乳液
US8609355B2 (en) 2011-07-26 2013-12-17 Indicator Systems International, Inc. Assays for the detection of microbes
FR2984328B1 (fr) 2011-12-20 2016-12-30 Bio-Rad Innovations Procede de detection d'une infection par le virus de l'hepatite c
EP2825191B1 (de) 2012-03-16 2019-08-28 University Health Network Lösliches toso protein und dessen verwendung zur behandlung von autoimmunerkrankungen
RU2520710C1 (ru) * 2012-12-10 2014-06-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО ЧелГМА Минздравсоцразвития России) Способ прогнозирования персистенции онкогенных типов вируса папилломы человека в цервикальном эпителии
CA2941693A1 (en) 2014-03-07 2015-09-11 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
RU2675108C2 (ru) * 2015-06-15 2018-12-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича" (ИБМХ) Композиция на основе синтетических пептидов и липидов для вакцины против гепатита с
WO2017011275A1 (en) 2015-07-10 2017-01-19 Nersissian Aram M Factor viii protein compositions and methods of treating hemophilia a
EP3365027B1 (de) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu-spezifische antikörper und deren verwendeng zur hemmung von biofilm
WO2018129092A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
US11564982B2 (en) 2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
AU2018236271B2 (en) 2017-03-15 2023-12-21 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CN114401986B (zh) 2019-07-08 2024-11-08 国家儿童医院研究所 破坏生物膜的抗体组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3400079A1 (de) * 1984-01-03 1985-07-11 Röhm GmbH, 6100 Darmstadt Wasserspreitendes kunststoffmaterial, verfahren zu seiner herstellung u. verwendung als verglasungs- und bedachungsmaterial
US4673634A (en) * 1985-03-08 1987-06-16 The United States Of America As Represented By The Department Of Health And Human Services Purified antigen from non-A, non-B hepatitis causing factor
JPS6391328A (ja) * 1986-10-07 1988-04-22 Mitsubishi Kasei Corp 非ａ非ｂ型肝炎抗原
NZ219516A (en) * 1987-02-10 1991-02-26 Wellcome Found Fusion proteins of hbcag (hepatitis b virus core antigen)
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
CN1074422C (zh) * 1987-11-18 2001-11-07 希龙股份有限公司 制备含有hcv表位的分离多肽的方法
US5191064A (en) * 1988-09-30 1993-03-02 The Research Foundation For Microbial Diseases (Osaka University) Non-a, non-b hepatitis virus antigen peptide
JPH02167081A (ja) * 1988-12-21 1990-06-27 Tetsuo Nakamura 非Ａ非Ｂ型肝炎ウイルスゲノムＲＮＡ、ｃＤＮＡおよびウイルス抗原蛋白質
JP2656995B2 (ja) * 1989-03-17 1997-09-24 カイロン コーポレイション Ｎａｎｂｖの診断用薬
EP0398748B1 (de) * 1989-05-18 2002-01-09 Chiron Corporation NANBV-Diagnostika: Polynukleotide, geeignet für Reihenuntersuchungen auf Hepatitis C-Virus
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
JP3156200B2 (ja) * 1989-09-15 2001-04-16 国立予防衛生研究所長 新規のｈｃｖ分離株
DE59109221D1 (de) * 1990-11-03 2001-11-15 Dade Behring Marburg Gmbh HCV-spezifische Peptide, Mittel dazu und ihre Verwendung
HU227510B1 (en) * 1991-09-13 2011-07-28 Novartis Vaccines & Diagnostic Immunoreactive hepatitis c virus polypeptide compositions

Also Published As

Publication number Publication date
JP2002167336A (ja) 2002-06-11
DE69232859D1 (de) 2003-01-16
ES2182822T3 (es) 2003-03-16
PL171972B1 (pl) 1997-07-31
US6303292B1 (en) 2001-10-16
FI941199A0 (fi) 1994-03-14
US5670153A (en) 1997-09-23
JP2005176853A (ja) 2005-07-07
DK0608261T3 (da) 2003-03-17
DE69232859T2 (de) 2003-04-10
RU2212899C2 (ru) 2003-09-27
US5728520A (en) 1998-03-17
JPH06511149A (ja) 1994-12-15
HU9400741D0 (en) 1994-06-28
JP4353905B2 (ja) 2009-10-28
BG98653A (bg) 1995-05-31
BG62973B1 (bg) 2000-12-29
PL171489B1 (pl) 1997-05-30
US5670152A (en) 1997-09-23
HU227510B1 (en) 2011-07-28
EP0608261A4 (de) 1995-03-15
HUT67342A (en) 1995-03-28
RO116199B1 (ro) 2000-11-30
FI112438B (fi) 2003-12-15
AU679429B2 (en) 1997-07-03
EP0608261B1 (de) 2002-11-27
JP2004073207A (ja) 2004-03-11
EP0608261A1 (de) 1994-08-03
RU2136311C1 (ru) 1999-09-10
CA2116764A1 (en) 1993-04-01
FI941199L (fi) 1994-04-27
US5756312A (en) 1998-05-26
AU2643692A (en) 1993-04-27
US5766845A (en) 1998-06-16
WO1993006126A1 (en) 1993-04-01
JP2008133301A (ja) 2008-06-12
CA2116764C (en) 1999-12-07

Similar Documents

Publication Publication Date Title
ATE228564T1 (de) Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden
FI935808A0 (fi) Hepatit-C-virus (HCV) polypeptider
RU94024561A (ru) Иммунореактивные композиции, способ получения композиции, способы получения и обнаружения антител, набор днк, клетка-хозяин, способ получения белка
EE200100292A (et) Peptiidligandidega kinnituvate mitmeste immunogeensete komponentidega HBV tuuma antigeensed osakesed
FI932561A0 (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
ATA117890A (de) Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
ATE496630T1 (de) Immunologische zusammensetzung und impfstoffe, die einen auf n-formyl-methionyl peptide bestehenden adjuvans enthalten
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DK0604418T3 (da) Isolerede viralproteincytokinantagonister
DK643387A (da) T-celle-epitoper af hepatitis b-virus-nucleocapsid-protein
DE59504181D1 (de) Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
DK0754704T3 (da) Syntetiske antigener til påvisning af antistoffer mod hepatitis c-virus
IL128826A0 (en) A crystallizable composition comprising a hepatitis C virus NS3 like polypeptide complexed with a NS4 a-like peptide
DE69232906T2 (de) Detektion des Hepatis-C Virus.
ES8500997A1 (es) Un metodo para producir un peptido.
IT1167607B (it) Polipeptide avente attivita' di interferon, composizione che lo contiene e procedimento di preparazione
IT8347557A0 (it) Polipeptide avente attivita' di interferon, composizione che lo conti ene e procedimento di preparazione
FI812859A7 (fi) Uudet karboksialkyyli-peptidit ja peptidien tioeetterit ja eetterit verenpainetta alentavina aineina.
ATE308618T1 (de) Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen
FR2676068B1 (fr) Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant.
DE3751834D1 (de) Selbstantigen der primären lebercirrhose
IT1164861B (it) Polipeptide avente attivita' di interferon, composizione che lo contiene e procedimento di preparazione
DK196689A (da) Ekspression af praes2-proteinet for hepatitis b i methylotrophe gaerarter
EP0503252A3 (en) Recombinant proteins having the immunoreactivity of hepatitis b virus e antigens (hbeag), method for their production and their application in immunoassays and as vaccines
FR2556971B2 (fr) Fractions polypeptidiques inductrices d'anticorps protecteurs contre des parasites du paludisme et compositions immunogenes les contenant

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0608261

Country of ref document: EP